The efficacy of salmeterol/fluticasone inhalation on systemic inflammatory markers in patients with chronic obstructive pulmonary diseases
Not Applicable
- Conditions
- chronic obstructive pulmonary diseases
- Registration Number
- JPRN-UMIN000008102
- Lead Sponsor
- Kawasaki Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
have any of tuberculosis or acute airway infections associated with bronchial asthma had COPD exacerbation in 4 weeks with pregnacy, lactating with any of severe heart disease, liver disease, renal disease, hematological disease or infection disease who the doctor in charge judge as to be excepted
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The changes of PARK/CCL-18, CC-16, serum arginase, and urinary beta isoprostane
- Secondary Outcome Measures
Name Time Method The changes of lung function